In today’s recent session, 0.48 million shares of the Heron Therapeutics Inc (NASDAQ:HRTX) have been traded, and its beta is 1.64. Most recently the company’s share price was $1.49, and it changed around -$0.06 or -3.87% from the last close, which brings the market valuation of the company to $219.54M. HRTX at last check was trading at a discount to its 52-week high of $3.93, offering almost -163.76% off that amount. The share price’s 52-week low was $1.04, which indicates that the recent value has risen by an impressive 30.2% since then. We note from Heron Therapeutics Inc’s average daily trading volume that its 10-day average is 2.0 million shares, with the 3-month average coming to 3.12 million.
Heron Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 3 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended HRTX as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Heron Therapeutics Inc is expected to report earnings per share of -0.03 for the current quarter.
Heron Therapeutics Inc (NASDAQ:HRTX) trade information
Instantly HRTX has been showing red trend so far today with a performance of -3.87% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.6300 on recent trading dayincreased the stock’s daily price by 8.59%. The company’s shares are currently down -12.35% year-to-date, but still down -5.70% over the last five days. On the other hand, Heron Therapeutics Inc (NASDAQ:HRTX) is 28.45% up in the 30-day period. We can see from the shorts that 29.98 million shares have been sold at a short interest cover period of 5.27 day(s).
The consensus price target as assigned by Wall Street analysts is $7, which translates to bulls needing to increase their stock price by 78.71% from its current value. Analyst projections state that HRTX is forecast to be at a low of $5 and a high of $9.
Heron Therapeutics Inc (HRTX) estimates and forecasts
Heron Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -57.06 percent over the past six months and at a 83.75% annual growth rate that is well above the industry average of 16.60%. The year-over-year growth rate is expected to be 10.88%, up from the previous year.
Consensus estimates provided by 3 financial analysts predict the company will bring in an average of 37.37M in revenue for the current quarter. Analysts predict that the company’s current quarter sales will jump, forecast at 9.15%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 20.01%. Heron Therapeutics Inc earnings are expected to increase by 83.89% in 2024, but the outlook is positive 47.50% per year for the next five years.
HRTX Dividends
Heron Therapeutics Inc’s next quarterly earnings report is expected to be released in January.
Heron Therapeutics Inc (NASDAQ:HRTX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.71% of Heron Therapeutics Inc shares, and 81.53% of them are in the hands of institutional investors. The stock currently has a share float of 82.12%. Heron Therapeutics Inc stock is held by 217.0 institutions, with RUBRIC CAPITAL MANAGEMENT LP being the largest institutional investor. By 2024-06-30, it held 17.6678% of the shares, which is about 26.71 million shares worth $93.5 million.
VANGUARD GROUP INC, with 5.6984% or 8.62 million shares worth $30.16 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
